Graft Versus Host Disease (GVHD) Market - By Disease Type, Treatment Type, Age Group, Route of Administration, Distribution Channel - Global Forecast 2024

Description

Graft versus host disease (GVHD) market size is estimated to register 8.1% CAGR between 2024 to 2032, driven by the increasing adoption of hematopoietic stem cell transplantation (HSCT) procedures, particularly in the treatment of hematologic malignancies and autoimmune disorders. As per National Institute of Health, approximately 50,000 stem cell transplants are conducted annually, experiencing an annual growth rate ranging between 10% to 15%. As HSCT remains a crucial treatment modality for various diseases, the incidence of GVHD is expected to rise correspondingly. Rapid advancements in medical technology and transplant procedures have led to improved survival rates among transplant recipients.

Increased awareness among healthcare providers and patients is further outlining the importance of early detection and prompt intervention in GVHD management. Timely diagnosis allows the initiation of appropriate treatment strategies, thereby reducing the severity of GVHD and improving patient outcomes. The ongoing R&D activities focused on the development of novel therapeutics with improved efficacy and safety profiles will further propel the market expansion.

The GVHD industry is segmented into disease type, treatment type, age group, route of administration, distribution channel and region.

Based on treatment type, the market size from the corticosteroids segment is anticipated to witness 7.8% growth rate through 2032, due to their potent anti-inflammatory and immunosuppressive properties. Corticosteroids are widely available in various formulations, including oral, intravenous, and topical preparations for offering flexibility in administration and enabling tailored treatment approaches based on the severity and site of GVHD manifestations.

With regards to route of administration, the oral segment in the graft versus host diseases market is anticipated to observe 8.4% CAGR during 2024-2032. Oral medications offer patients convenience and ease of administration ensuring self-management outside of clinical settings and promoting adherence to treatment regimens. This accessibility is enhancing patient compliance while leading to improved treatment outcomes and overall quality of life.

Asia Pacific graft versus host disease industry will record impressive growth at 8.5% CAGR over 2024-2032. This can be attributed to the rising incidence of hematopoietic stem cell transplantation (HSCT) procedures, particularly in countries with growing healthcare infrastructure and improved access to transplant services. Rising collaborations between local healthcare institutions, pharmaceutical companies, and research organizations is fostering the development of novel GVHD therapies tailored to the clinical needs, further stimulating the regional market growth.

Product Code: 8768

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of hematological disorders
  - 3.2.1.2 Advancements in transplantation techniques
  - 3.2.1.3 Rising investments in research and development
  - 3.2.1.4 Growing pipeline of therapeutic agents
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High treatment cost
  - 3.2.2.2 Stringent regulatory challenges
  - 3.2.2.3 Risk of complications and relapse
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Acute graft versus host disease (aGVDH)
5.3 Chronic graft versus host disease (cGVDH)

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Monoclonal antibodies
6.3 mTOR inhibitors
6.4 Tyrosine kinase inhibitors
6.5 Immunosuppressants
6.6 Corticosteroids
6.7 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 < 20 years
7.3 21-50 years
7.4 51 years and above

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Oral
8.3 Intravenous
8.4 Topical

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

11.1 Astellas Pharma Inc.
11.2 Bristol Myers Squibb
11.3 ElsaLys Biotech SA
11.4 Incyte Corporation
11.5 Johnson & Johnson Services, Inc.
11.6 Kiadis Pharma
11.7 Mallinckrodt Pharmaceuticals
11.8 Merck & Co., Inc.
11.9 Mesoblast Ltd
11.10 Neovii Pharmaceuticals AG
11.11 Novartis AG
11.12 Pfizer Inc.
11.13 Sanofi
11.14 Soligenix

Graft Versus Host Disease (GVHD) Market - By Disease Type, Treatment Type, Age Group, Route of Administration, Distribution Channel - Global Forecast 2024 - 2032